Compare AMPH & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPH | GERN |
|---|---|---|
| Founded | 1996 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.8M | 821.1M |
| IPO Year | 2005 | N/A |
| Metric | AMPH | GERN |
|---|---|---|
| Price | $18.18 | $1.26 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 3 |
| Target Price | ★ $28.38 | $2.17 |
| AVG Volume (30 Days) | 644.5K | ★ 14.2M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $719,887,000.00 | N/A |
| Revenue This Year | $6.90 | $26.91 |
| Revenue Next Year | $4.64 | $43.75 |
| P/E Ratio | $130.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.65 | $1.04 |
| 52 Week High | $31.26 | $2.01 |
| Indicator | AMPH | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 32.94 |
| Support Level | $17.03 | $1.24 |
| Resistance Level | $20.08 | $1.29 |
| Average True Range (ATR) | 0.81 | 0.09 |
| MACD | -0.21 | -0.02 |
| Stochastic Oscillator | 19.16 | 10.42 |
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.